Market Trends of Acute Myeloid Leukemia Industry
This section covers the major market trends shaping the Acute Myeloid Leukemia Market according to our research experts:
Cytarabine is Expected to Witness High Growth Over the Forecast Period
Cytarabine can treat different leukemia forms, including acute and chronic myelogenous leukemia (AML and CML), acute lymphocytic leukemia (ALL), and acute promyelocytic leukemia (APL). It can also treat Hodgkin's lymphoma, meningeal leukemia, and other types of lymphoma (cancers found in the lining of the brain and spinal cord). Due to its effectiveness in treating acute myeloid leukemia, Cytarabine is widely used during chemotherapy. Organizations working for cancer, such as Macmillan Cancer Support, have stated that Cytarabine is more effective for acute myeloid leukemia, which is why the drug is used widely. Therefore, this sub-segment is expected to have a significant market share in the chemotherapy segment.
Rising approvals for Cytarabine by the US Food and Drug Administration for treating acute myeloid leukemia are also expected to drive the growth of this market. For Instance, in March 2021, Jazz Pharmaceuticals PLC received US Food and Drug Administration (FDA) approval for a revised label for Vyxeos (daunorubicin and Cytarabine), including a new indication to treat newly-diagnosed therapy-related acute myeloid leukemia (t-AML) or AML with myelodysplasia-related changes (AML-MRC) in pediatric patients aged one year and older. Furthermore, in January 2022, the US Food and Drug Administration (FDA) granted the company orphan drug designation for its pipeline compound OM-301 to treat acute myeloid leukemia (AML) developed by Oncolyze Inc. These approvals from the regulatory authorities are driving the growth of the market.
Therefore, owing to the abovementioned factors, the cytarabine segment is expected to show a significant share during the forecast period.
North America Holds a Major Share and Expected to do Same during the Forecast Period
North America currently dominates the market for acute myeloid leukemia and is expected to continue its stronghold over the forecast period. The rising prevalence of acute myeloid leukemia cases in the US is expected to drive the growth of this market in this region. For instance, according to the American Society of Clinical Oncology in 2021, acute myeloid leukemia is a rare malignancy that accounts for around 1% of all cancers. In the US, an estimated 20,240 people of all ages (11,230 men and boys and 9,010 women and girls) were diagnosed with this disease in 2021. AML is the second most prevalent kind of leukemia in adults and children, with adults accounting for the majority of occurrences. Therefore, the rising prevalence of acute myeloid leukemia in the US will lead to higher therapy adoption for this disease, thereby expected to drive the growth of this market in North America.
Furthermore, rising research and development and product launches for acute myeloid leukemia are further expected to drive market growth in this region. For instance, in May 2022, the FDA approved ivosidenib (Tibsovo, Servier Pharmaceuticals LLC) in combination with azacitidine (azacitidine for injection) for newly diagnosed acute myeloid leukemia (AML). It includes a susceptible IDH1 mutation detected by an FDA-approved test in adults 75 years or older or with comorbidities that preclude intensive induction chemotherapy.
Therefore, the market is expected to show a significant share in North America due to the abovementioned factors.
